The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Dietary Sodium Reduction Fails to Reduce Clinical Heart Failure Events
Findings from SODIUM-HF suggest strategies to reduce dietary sodium intake to less than 1500 mg daily were not more effective than usual care in reducing hospitalization risk.
Mavacamten Reduces Eligibility for SRT in Obstructive Hypertrophic Cardiomyopathy
Findings from VALOR-HCM suggest more data is needed to assess the durability of improvement in septal reduction therapy eligibility over longer time periods.
Treating Mild Chronic Hypertension in Pregnancy May Reduce Risk of Neonatal, Fetal Outcomes
New late-breaking ACC 2022 data support the use of antihypertensive therapy to reduce risk of events including preeclampsia and neonatal death among at-risk expecting mothers.
Lack of Interaction Observed For Treatment Effect of Empagliflozin By Region, Race
New research suggests a consistent risk reduction of empagliflozin may be theorized independent of region or race categories.
Valvular Heart Disease Increasingly Prevalent in Older Americans
An investigator discusses new ACC 2022 data showing valvular heart disease is disparately impacting older patients, as well as females, with previously unanticipated manifestations.
Omecamtiv Mecarbil Reduces Risk of CV Death in Hospitalized Patients with HFrEF
Hospitalized HFrEF patients had a higher rate of the cardiovascular death or a worsening heart failure event than outpatients
How New Heart Failure Guidelines Recommend SGLT-2 Inhibitor Use
Guideline writing committee co-chair Biykem Bozkurt, MD, PhD, discusses the utility of the drug class in HF prevention and risk reduction.
Psoriatic Treatment Does Not Increase Risk of COVID-19 Infection
Furthermore, psoriatic treatment did not appear to significantly reduce COVID-19 vaccine efficacy.
Influencers, Not Dermatologists, Hold Court on TikTok Skin of Color Subjects
A new AAD study shows board-certified experts produce only one-fourth of the most popular TikTok posts on subjects in their field.
Guselkumab Provides Consistent Psoriasis Clearance Over 5 Years
An assessment of long-term VOYAGER 1 and 2 trial data show the IL-23 biologic provides significant benefit toward skin clearance, regardless of baseline characteristics.
Study: 7 in 10 Vitiligo Patients Have Familial History of Disease
The VALIANT study featured a cross-sectional online survey that was used to recruit adult patients 18 years and older who were professionally diagnosed with vitiligo.
Lebrikizumab Reduces Disease Severity in Patients with AD
Data from the ADhere studies found that lebrikizumab was well tolerated in patients with atopic dermatitis.
Will a Drug Get Approved for Epidermylosis Bullosa?
A pair of novel topical drugs hit high phase 3 marks at AAD 2022. One expert explains how they both may reach ground-breaking indications.
Bimekizumab Provides Long-Term Psoriasis Skin Clearance
Clinical responses including PASI 100 and absolute PASI, and PASI ≤2 were maintained through week 96 with the biologic in patients with psoriasis, with no new safety signals identified.
Berdazimer Gel Clears Pediatric Molluscum Contagiosum in Phase 3 Trial
New AAD 2022 data support the novel gel therapy as the potentially first treatment for the viral-borne skin condition.
EDP1815 Well Tolerated in Patients with Mild to Moderate Psoriasis
The new oral medicine helped some patients with mild to moderate psoriasis achieve and sustain PASI-50 after the initial study period.
Advancing Pediatric Dermatology Biologics and Symptom Scoring
Amy S. Paller, MD, concludes her AAD 2022 interview with a look into the future of pediatric systemic therapy—and a call to assure due diligence in tracking patient progression among her peers.
Oleogel-S10 Significantly Improves Epidermolysis Bullosa Wounds at 12 Months
Dedee F. Murrell, MD, details the EASE trial findings presented at AAD 2022, and what the benefit of the novel topical gel may mean for patients with EB.
Study Defines 6 Most Common Contact Dermatitis Allergens in Younger, Older Children
A new AAD 2022 study shows disparities in patch testing for allergens—and how certain fragrances, metals and preservations discriminately affect rates of contact dermatitis.
Ritlecitinib Generally Safe and Tolerated for Alopecia Areata
The ALLEGRO study detailed the efficacy and safety of ritlecitinib in adult and adolescent patients with the alopecia areata.
Dupilumab, Biologics for the Youngest Atopic Dermatitis Patients
The agent may become approved this year for children aged 6 months to 5 years old. Amy S. Paller, MD, discusses what impact it could bring.
Difelikefalin Treatment Improves Symptoms of Itch-Dominant AD
New phase 2 data from the KARE study presented at AAD found that the therapy improved itch severity and sleep in patients with atopic dermatitis and pruritis.
Detailing Potential Dermatology Drug Approvals from AAD 2022
Dr. Raj Chovatiya provides updates from AAD on some pending and potential FDA approvals for several dermatology therapies.
Baricitinib Treatment Leads to Hair Regrowth in Alopecia Areata
With no approved therapies currently available, Dr. Brett King feels that the JAK inhibitor baricitinib could provide patients with a long sought after solution to hair loss.
Topical Gene Therapy B-VEC Reaches Phase 3 Efficacy Endpoints for DEB Disease Reversal
New AAD 2022 data show the novel gene therapy from Krystal Biotech provided wound healing by 3 months in patients with dystrophic epidermolysis bullosa.
The Potential of Dupilumab Treatment for Prurigo Nodularis
Dr. Gil Yosipovitch suspects that dupilumab will be approved for use in patients with prurigo nodularis based on new data from the LIBERTY-RN PRIME2 trial.
Amy S. Paller, MD: Systemic Atopic Dermatitis Therapy for Pediatric Patients
The Feinberg School of Medicine expert discusses the impact of dupilumab and other biologics on severely affected children and adolescnets.
How Autoimmune Disease Risks Heightens After SARS-CoV-2
An expert delves into the increased risk of conditions including psoriasis flares, lupus, and scleroderma following COVID-19.
Addressing Cardiometabolic Disease in Patients with Psoriasis
New phase 4 data suggests that apremilast could be used to improve cardiometabolic function in patients with psoriatic disease.
Positive Long-Term Safety Data for Tralokinumab in Patients with AD
Data from the 5-year extension trial ECZTEND indicated that the overall safety profile of tralokinumab was consistent with the previous ECZTRA trials.